Pharmaceutical company Organon (NYSE:OGN) will be reporting earnings tomorrow before market hours. Here’s what investors ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Boston: Alloy Therapeutics Inc., a biotechnology ecosystem company has announced its latest strategic collaboration with ...

During the COVID-19 pandemic, Pfizer leveraged Kore.ai’s AI agent platform to deploy a multilingual support system across 17 ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...